Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.
Will Trikafta Drive Vertex's (VRTX) Revenues in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.
Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization
by Zacks Equity Research
Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.
Will Eli Lilly (LLY) Beat Estimates This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.
Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes
by Zacks Equity Research
Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar
by Zacks Equity Research
Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod
by Zacks Equity Research
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
What's in Store for UnitedHealth (UNH) This Earnings Season?
by Zacks Equity Research
UnitedHealth's (UNH) earnings results are likely to reflect solid contribution from its segments, namely Healthcare and Optum, partly offset by higher claim costs.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
by Zacks Equity Research
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
by Zacks Equity Research
Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.
The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx
Top Analyst Reports for Coca-Cola, Merck & Royal Dutch Shell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola (KO), Merck (MRK), and Royal Dutch Shell (RDS.A).
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.52, marking a +0.92% move from the previous day.
Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
FATE Surges More Than 152% in Three Months: Here's Why?
by Zacks Equity Research
FATE's recent positive pipeline updates have led to a significant upsurge in the stock price.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $58.49 in the latest trading session, marking a -1% move from the prior day.
Here's Why Lilly (LLY) Has Outperformed the Industry This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make antibodies to treat COVID-19.
The Zacks Analyst Blog Highlights: PayPal, Shopify, BP p.l.c., Gilead Sciences and Southern Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PayPal, Shopify, BP p.l.c., Gilead Sciences and Southern Co
Top Research Reports for PayPal, Shopify & BP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings (PYPL), Shopify (SHOP) and BP p.l.c. (BP).
Company News for Dec 17, 2020
by Zacks Equity Research
Companies In The News Are: GOOGL, LUV, TLRY, APHA, GLPG, GILD.